These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 28464828

  • 1. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW, Long J, Huntington JA.
    BMC Infect Dis; 2017 May 02; 17(1):316. PubMed ID: 28464828
    [Abstract] [Full Text] [Related]

  • 2. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
    Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJ.
    J Antimicrob Chemother; 2017 Mar 01; 72(3):900-905. PubMed ID: 27999024
    [Abstract] [Full Text] [Related]

  • 3. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
    Scott LJ.
    Drugs; 2016 Feb 01; 76(2):231-42. PubMed ID: 26746849
    [Abstract] [Full Text] [Related]

  • 4. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C.
    Clin Infect Dis; 2015 May 15; 60(10):1462-71. PubMed ID: 25670823
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Xiao AJ, Huntington JA, Long J, Caro L.
    Int J Antimicrob Agents; 2018 Sep 15; 52(3):324-330. PubMed ID: 29596902
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V, Foo J, Ahir H, Sarpong E, Merchant S.
    J Med Econ; 2017 Aug 15; 20(8):840-849. PubMed ID: 28532194
    [Abstract] [Full Text] [Related]

  • 10. Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.
    Miller B, Popejoy MW, Hershberger E, Steenbergen JN, Alverdy J.
    Antimicrob Agents Chemother; 2016 Jul 15; 60(7):4387-90. PubMed ID: 27139477
    [Abstract] [Full Text] [Related]

  • 11. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C, Solomkin J.
    Expert Opin Pharmacother; 2015 Feb 15; 16(2):271-80. PubMed ID: 25529765
    [Abstract] [Full Text] [Related]

  • 12. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan 15; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
    Armstrong ES, Mikulca JA, Cloutier DJ, Bliss CA, Steenbergen JN.
    BMC Infect Dis; 2016 Nov 25; 16(1):710. PubMed ID: 27887579
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.